Lytenava (bevacizumab gamma) is the first version of bevacizumab licensed in the UK and Europe specifically for injection into the eye to treat wet (neovascular) age-related macular degeneration. Private self-pay cost is from around £750 per intravitreal injection as a UK 2026 guide, including the procedure. Most patients need an initial loading course of three monthly injections, then ongoing treatment guided by OCT scans.
What Lytenava is
Bevacizumab is an anti-VEGF medicine that blocks the growth signal driving the abnormal, leaking blood vessels of wet AMD. It has been used to treat wet AMD worldwide for many years, but historically only as an off-label product repackaged from a cancer medicine. Lytenava is the first bevacizumab formulated, manufactured and licensed specifically for use inside the eye — a regulated, quality-assured product made for ophthalmic injection, at a fraction of the cost of the branded alternatives.
It is given as an intravitreal anti-VEGF injection and is an option for adults with active wet AMD confirmed on OCT scanning.
How treatment works
After numbing drops and a sterile prep, the consultant gives a quick injection of Lytenava into the vitreous gel through the white of the eye. The drug reduces the leakage and growth of the abnormal vessels, drying the macula so vision can stabilise or improve. Treatment follows the standard anti-VEGF pattern: three loading injections about a month apart, then a personalised treat-and-extend schedule based on how the macula responds on OCT.
New distortion or a blurred central patch? Wet AMD needs prompt assessment to protect your vision.
Book an urgent assessmentCost of private Lytenava injections
As a UK 2026 guide, private Lytenava is from around £750 per intravitreal injection, making it the most cost-effective licensed anti-VEGF option — typically less than branded agents such as aflibercept or faricimab. Your total cost depends on how many injections you need: a loading course is three injections, after which the interval is extended as far as your macula allows. The first consultant assessment with OCT is charged separately. Compare options on our wet AMD treatment page or the full price guide. Prices are a guide and confirmed after assessment.
Frequently asked questions
How much does a private Lytenava injection cost in the UK?
As a UK 2026 guide, private Lytenava is from around £750 per intravitreal injection. Because it is the first bevacizumab licensed specifically for the eye, it is typically the most cost-effective licensed anti-VEGF option. Most patients need three loading injections, then treatment is extended as the macula allows.
What is Lytenava and how is it different from Avastin?
Lytenava (bevacizumab gamma) is the same molecule as the bevacizumab in Avastin, but it is the first product formulated, manufactured and licensed specifically for injection into the eye. That means a regulated, quality-assured ophthalmic product rather than an off-label repackaged cancer medicine.
How many Lytenava injections will I need?
Treatment usually begins with three loading injections about a month apart, then a personalised treat-and-extend schedule. The number of injections after that depends on how your macula responds on OCT scans, which guide each decision.
Is Lytenava as effective as other anti-VEGF drugs?
Bevacizumab has decades of real-world use in wet AMD and large independent trials have shown it works comparably to ranibizumab for vision. Lytenava brings that molecule into a licensed, eye-specific product. Your consultant advises which anti-VEGF best fits your eye and circumstances.